Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 31:53:23-26.
doi: 10.1016/j.jdcr.2024.07.011. eCollection 2024 Nov.

Relapsing toxic epidermal necrolysis following COVID-19

Affiliations
Case Reports

Relapsing toxic epidermal necrolysis following COVID-19

Feben Messele et al. JAAD Case Rep. .
No abstract available

Keywords: COVID-19; SJS; Stevens-Johnson syndrome; TEN; relapsing; toxic epidermal necrolysis.

PubMed Disclaimer

Conflict of interest statement

Dr Min is on the advisory boards of Horizon, McGraw Hill, and BMS and is an investigator for Amgen, BI, MBS, and Priovant. Dr Rojek has served on the advisory board of Boehringer Ingelheim. The other authors have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Examination after day 3 of initial IVIG treatment. Diffuse morbilliform eruption with bullae formation overlying dusky skin necrosis involved the (A) mucosal lips, neck, chest, (B) back, and (C) extremities. Examination on day 8. Dusky and necrosed papules coalescing into plaques with overlying flaccid and hemorrhagic bullae are seen on (D) the face and mucosal lips, (E) trunk including her back, and (F) extremities. Subsequent presentation, 6 days after discharge from initial presentation. G, Hemorrhagic crust on the lips. H, Diffuse erythroderma and erosions on the back with skin sloughing. I, Dusky papules coalescing into plaques with overlying flaccid and hemorrhagic bullae on the lower extremities.
Fig 2
Fig 2
Shave biopsy revealed (A, C) a subepidermal split with areas of full-thickness epidermal necrosis and (B, C) interface dermatitis with scattered necrotic keratinocytes. (A-C, Hematoxylin-eosin stain; original magnifications: A, ×4; B and C, ×40.)

References

    1. Frantz R., Huang S., Are A., Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas) 2021;57(9):895. doi: 10.3390/medicina57090895. - DOI - PMC - PubMed
    1. Zou H., Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol. 2023;64(1):e1–e10. doi: 10.1111/ajd.13958. - DOI - PMC - PubMed
    1. Curtis K.K., Dillan M.M., Sharma T.R., Piktel J. COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort analysis. J Am Acad Dermatol. 2024;90(6):1300–1302. doi: 10.1016/j.jaad.2024.02.029. - DOI - PubMed
    1. Stanley E.A., Zhang L., O’Hara J., Haertsch P., Maitz P. The seven-fold rise in incidence of Stevens-Johnson syndrome & toxic epidermal necrolysis: associations with COVID-19 and the vaccine. Burns. 2024;50(1):87–92. doi: 10.1016/j.burns.2023.06.016. - DOI - PubMed
    1. Malviya M., Barua S., Shenoy M.A., Ullah A.M. Paxlovid-associated Stevens-Johnson syndrome. Chest J. 2023;164(4):A2062–A2063. doi: 10.1016/j.chest.2023.07.1410. - DOI

Publication types

LinkOut - more resources